×

RNS Number : 4184W

First Derivatives PLC

27 April 2016

 

First Derivatives plc

("FD" or the "Group")

 

Strategic Partnership with Thomson Reuters for Streaming Analytics

 

FD (AIM: FDP.L, ESM: FDP.I) announces a strategic partnership for the use of its Kx technology with Thomson Reuters to power the latest version of their financial Data as a Service platform, Velocity Analytics. The agreement follows a comprehensive review of real-time and in-memory technologies by Thomson Reuters.   

 

Velocity Analytics combines real-time and reference data with Thomson Reuters' deep tick history database to provide clients with market data for use by quantitative analysts, traders and compliance departments across the financial services industry. It provides both pre-built and custom analytics on enriched market data from more than 70 exchange, broker and vendor data sources. This enables clients to create their own data repository for analytics, compliance and other use cases.

 

A growing pipeline of buy-side and sell-side firms are currently evaluating the service, with several strategic customers engaged in an early adoption programme. The service will be delivered from the world's largest private financial markets Cloud network, Thomson Reuters Elektron.

 

Mike Powell, managing director for enterprise capabilities, Financial & Risk, at Thomson Reuters, commented: "Given Thomson Reuters' global customer footprint and the demand across the industry for streaming analytics and market insight driven by increasingly quantitative trading strategies and regulatory reporting requirements, demand should be strong for this solution. We are pleased to be working with FD to power Velocity Analytics using Kx technology."

 

Brian Conlon, Chief Executive Officer of FD, commented: "FD is pleased to partner with Thomson Reuters, using the ability of our Kx technology to enable real-time analytics on very large datasets to power the Velocity Analytics service. This agreement significantly increases our channel to market and the service will be rapidly deployed to customers through Thomson Reuters Elektron, which will accelerate our growth in this market."

 

 

Enquiries

For further information please contact:

First Derivatives plc Brian Conlon, Chief Executive Officer Graham Ferguson, Chief Financial Officer Ian Mitchell, Head of Investor Relations	+44(0)28 3025 2242 www.firstderivatives.com
Investec Bank plc (Nominated Adviser and Broker) Dominic Emery Carlton Nelson Sebastian Lawrence	+44 (0)20 7597 4000
Goodbody (ESM Adviser and Broker) Linda Hickey Finbarr Griffin	+353 1 667 0420
Walbrook PR Paul Cornelius / Nick Rome / Helen Cresswell / Sam Allen	+44 (0)20 7933 8780

 

About FD

FD is a global technology provider with 20 years of experience. The Group's Kx technology is used by some of the world's largest finance, technology and energy institutions. FD employs over 1,500 people worldwide and has operations in London, New York, Stockholm, Singapore, Hong Kong, Tokyo, Sydney, Palo Alto, Toronto, Philadelphia, Dublin, Belfast and its headquarters in Newry.

 

For further information, please visit www.firstderivatives.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCEASLKALFKEFF

Close

×

RNS Number : 3121W

Nasstar PLC

26 April 2016

 

The Quest for Microsoft Gold: Nasstar PLC Announces Their Microsoft Gold Certification

 

LONDON, UNITED KINGDOM–(Marketwired – April 26, 2016) – Nasstar PLC (LSE: NASA) today announced that they had achieved the coveted Microsoft Gold Hosting Partner certification for their datacenter hosting operations.

 

Nasstar PLC is now an accredited Microsoft Gold Hosting Partner, certified by Microsoft and able to deliver solutions that meet Microsoft's stringent demands within its field of expertise. 

 

The Microsoft Gold Hosting Partner accreditation certifies that Nasstar PLC has an in-depth and highly qualified technical resource, a proven track record in delivery and strict procedures and guidelines that are adhered to in each and every hosted solution provided.

 

Nasstar CEO Nigel Redwood said today, "Achieving our Microsoft Gold Hosting Certification was an important milestone for Nasstar and our technical team, senior management and board of directors are all justifiably proud of this fantastic achievement."

 

Nasstar Head of Infrastructure Shannon Johnston said today, "The certification process is incredibly hard and rightly so, it encompasses customer references, employee certifications, SPLA revenues, technical certification, multiple accreditations and a solid track record."

 

Nasstar plans to tell the story of their journey through the Microsoft Gold Hosting Partner accreditation process by hosting a webinar entitled The Quest for Microsoft Gold.

 

The live webinar will be held on Weds May 18 at 11:00 AM BST (London).

 

To attend the webinar, please register using this link: http://bit.ly/MicrosoftGold

 

ABOUT NASSTAR PLC: Nasstar PLC is a managed IT services provider to the recruitment, legal, financial, logistics and government sectors. Nasstar provides fully managed and fully hosted IT services from their ISO27001 security standard certified datacenters, encompassing hosted desktops/applications and managed networks.

 

Nasstar PLC is listed on the London Stock Exchange under the ticker symbol NASA.

 

Nasstar PLC, Datapoint House, Telford, TF1 7UL, United Kingdom | 01952 225 000 
Website: www.nasstar.com   INFORMATION

 

Nasstar PLC
Lydia Cooper
lydia.cooper@e-know.net
www.nasstar.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

ALLUNUVRNVASURR

Close

×

RNS Number : 2857W

Midatech Pharma PLC

26 April 2016

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide

 

~ Release profile of Midatech's Q-Octreotide compared favourably with the reference product and current market leader ~

 

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces positive pharmacokinetic data with its Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome. The pilot preclinical study confirmed the systemic release profile of Midatech's Q-Octreotide compared favourably with the reference Octreotide product and current market leader, Sandostatin® LAR Depot (Novartis).

 

Commenting on the announcement, Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "Q-Octreotide is one of the most advanced of our in-house cancer treatments. Whilst preparing the programme for clinical development, the existing use of Octreotide gives us confidence that this programme can be progressed quickly. We look forward to continuing to develop our internal pipeline of cancer therapies with Q-Octreotide near the front. Furthermore we are delighted now to be progressing with the investment in commercial scale up of production in our Bilbao facility in Spain, which will enable Q-Octreotide and other projects to be manufactured in-house, enabling us to capture more of the integrated value chain."

 

MTD201, a sustained release version of Octreotide, is used to treat the incapacitating symptoms of metastatic carcinoid tumours, where it suppresses or inhibits the severe diarrhoea and flushing episodes associated with the disease, and to normalise the over-production of growth hormone in people suffering acromegaly who have had inadequate response to other therapies. Midatech plans on submitting its investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) and begin bio-equivalence studies in late 2016.

 

Q-Octreotide is a wholly-owned asset of Midatech Pharma and will continue to be developed in-house. Subject to regulatory approval, Midatech expects to commercialize Q-Octreotide in the United States through its Midatech Pharma U.S. subsidiary. 

 

– ENDS –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Atholl Tweedie / Duncan Monteith

Corporate Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

RBC Europe Limited (Joint Broker)

Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman

Tel: +44 (0)207 653 4000

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

Forward Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the anticipated benefits of Q-Octreotide, preclinical results, the filing and timing of an IND with respect to Q-Octreotide and the receipt of any regulatory approvals, commercialization plans and other statements that are not historical fact. Any forward-looking statements are based on currently available data together with management's views and assumptions regarding future events and performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements, including but not limited to, operational challenges in achieving our strategic objectives and executing plans.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission ("SEC"), which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCLFFLLSFIEFIR

Close

×

RNS Number : 9542V

Galileo Resources PLC

21 April 2016

 

For immediate release: 14.00

 

21 April 2016

Galileo Resources Plc

("Galileo" or "the Company")

 

 

GALILEO EXECUTES EXCLUSIVE AGREEMENT FOR FARM-OUT OF THE COMPANY'S SILVERTON GOLD PROPERTY IN NEVADA USA

 

Galileo is pleased to announce that it has executed a binding and exclusive term sheet  ("Exclusive Agreement") with Orogen Gold plc, ("Orogen"), pursuant to which Orogen will have the right to earn-in a 51% interest in the Company's Silverton Gold Silver property ("Silverton" or the "Property") in Nevada, USA, by way of exploration expenditure of US$400,000 (the "First Expenditure") within 18 months on the Property and thereafter the possibility to spend an additional US$1,500,000 (the "Second Expenditure") within 30 months to earn-in a further 24% interest in the Property (the "Farm-out").

 

The Company will have the right to participate pro rata after the First Expenditure; should it exercise this right it would retain a 49% equity interest in Silverton (as opposed to being diluted down to 25%). The Exclusive Agreement is subject to due diligence, which is anticipated to be completed, within 45 days of signing, including formalisation of the Exclusive Agreement.

 

Shareholders are advised that Colin Bird is an executive director of both Galileo and Orogen, in which he holds respectively 24.81% and 1.82% of their issued ordinary share capital. In accordance with the requirements of Sections 171 to 177 of the Companies Act 2006, he has abstained from negotiations and the decision making process of the Galileo Board in regard to the Farm-Out and will continue to do so in order to manage any future potential for a conflict of interest in the Property. 

 

Highlights

 

·     Galileo has granted Orogen the right to earn an initial 51% interest in the Silverton project over the 6km² claim area through exploration spend of US$400,000 over 18 months

·     Orogen may earn an additional 24% interest in the project through a further exploration spend of US$1.5 million over a subsequent 30 month period

·     Previous bedrock and drill sampling outlined an area >0.5g/t Au measuring 1km x 0.5km

·     Farm-out allows for outside investment into Silverton and is in line with Galileo's strategy of focusing its available resources on its South African copper projects

·     Assay intervals reported by Newcrest (2003) up to 7.62m@ 2.29g/t Au and 10.67m @ 1.0g/t, including 1.52m @ 5.01g/t Au (non-Code compliant)

·     Historic silver and gold production from district

·     Shear Zone target never drill tested for gold-silver mineralisation; adjacent short holes returned assays up to 1.71g/t Au, 604g/t Ag over 1.52m intervals within wider intervals of lower grades

·     This proposed transaction allows Galileo to continue with its key focus on copper

 

Andrew Sarosi, an executive director of Galileo, has advised the board's non-executive directors and commented: "We are pleased to have entered into this Exclusive Agreement with Orogen, which will allow for an outside party to fund the exploration of Silverton, in particular focusing on a highly anomalous gold shear zone, on which limited vertical drilling (reverse circulation) has been previously carried out, whilst allowing Galileo to retain upside through its residual equity interest.

 

We intend to focus our resources on copper exploration, for which in March 2016, the Company raised funds primarily for its Concordia copper project in South Africa. This proposed transaction enables Galileo to retain an interest in Silverton, while focussing on its copper mission.  Orogen has confirmed to Galileo that it has sufficient funds in place to commence work on the Property."

The Property  

The Property is located northeast of Tonopah in the central Pancake Range. The Silverton claim block comprises 72 lode claims staked by Newcrest in March 2002. 

 

Small-scale mining operated in the area from 1930 to 1937 and in 1953.  Total production for the district is <100,000 oz. silver, <2,000 oz. gold and <1 ton of antimony.  Over the last three decades multiple companies including Olympic Mining, Westgold, Newmont and Pittston have explored the property for gold and silver.  Work completed comprised geochemical sampling, fluid inclusion studies, mapping, geophysics and drilling (~45 pre-Newcrest holes). 

 

Since 2002 Newcrest has taken over 1,000 rock chip samples and drilled 42,983 ft in 29 RC (reverse circulation) drill holes.

 

Geology/Mineralization

 

The Silverton district occurs at the eastern margin of a caldera complex dated at 34Ma.  Both high and low angle faults and fault breccias related to caldera rim tectonics are observed on the property.  Rocks consist of Palaeozoic dolomite/limestone detachment blocks surrounded and underlain by Tertiary rhyolite tuffs.  Rhyolite dikes have also been mapped along caldera ring fractures and north trending faults. 

Tuffs around the Palaeozoic rocks are locally bleached and argillized (kaolinite – clay).  Both units are silicified along faults, generally as jasperoid bodies up to 30 ft. wide.  Jasperoid also forms flat-lying replacement horizons within volcanic beds.  Additional silicification includes, stockwork silica veining and chalcedony +- stibnite-pyrite veins.  One to two percent disseminated pyrite and minor stibnite occurs in tuffaceous rocks over a 4mi2 area.  Other mineralization includes barite, gypsum, and alunite.  Ore-grade gold values are generally associated with veins, strongly veined limestone, and argillized tuff along mineralized structures and adjacent to jasperoid.  Most jasperoid bodies themselves contain only low-level gold. 

The property contains a >100ppb Au rock chip anomaly measuring 2.5km x 3km.  Au, Ag, As, and Hg mineralization are broadly coincident.  Within the anomaly, the most significant of three main zones is a NNE trending area (Silverton Shear) >0.5g/t Au measuring 1km x 0.5km and centered on a 100m wide silicified contact between rhyolite to the east and carbonate rocks to the west.  

Old vertical drilling on the southern end of the Silverton Shear returned several intervals of 5ft @ 1-5g/t Au and 100-600g/t Ag.  The best Newcrest intercept is 25 feet @ 2.3g/t Au in rhyolite tuff.

Geophysics

Resistivity and ground magnetic surveys were completed in 1998 and 1999.  Regional aeromagnetics also covered the Property. 

Metallurgy

No metallurgical testing has been done on rocks from the Silverton district and potential recoveries are unknown.  However, gold occurrence could be fine grained, micron sized, as none is observed in pan concentrates.

Exploration Potential

The geologic environment is similar to disseminated and bonanza epithermal gold mineralisation at the Round Mountain mine Nevada. The Silverton property and area of volcanic rocks to the west are prospective for exposed and concealed oxide and sulphide tuff- and intrusion -hosted disseminated and associated and/or carbonate-hosted bonanza style epithermal gold mineralisation. In the relatively untested area along the 1 km Silverton shear zone, with a 0.1-1.5g/t Au anomaly at surface, the potential exists for bonanza gold silver 'feeder' veins. In addition, low-grade bulk tonnage disseminated gold can also occur in the rhyolite porphyry intrusions, similar to e.g. Kori Kollo in Bolivia.

 

Additional information on Silverton

Galileo's accounts do not include a specific carrying cost for the Property, which was acquired as part of the acquisition of the unlisted St Vincent Minerals Inc. (SVM) and whose accounts did not include a separate carrying cost for the Property. The only costs associated with the Property and incurred to date by Galileo are the annual Bureau of Land Management and County fees, which amount to approximately US$11,900.  

 

Related Party Transaction

 

Given Colin Bird's position as CEO of both Galileo and Orogen and his shareholdings of 24.81% and 1.82% respectively, the Farm-Out is a related party transaction under the AIM Rules. Accordingly, Mr Sarosi, Galileo's executive director, and its non-executive directors, having liaised with the Company's Nominated Adviser, consider that the terms of the Farm-Out are fair and reasonable in so far as its shareholders are concerned.

 

 

Technical Sign-Off

Andrew Sarosi, Executive Director of Galileo, holds a B.Sc. Metallurgy and M.Sc. Engineering, University of Witwatersrand, is a member of The Institute of Materials, Minerals and Mining and is 'qualified person' as defined under the AIM Rules for Companies and a competent person under the reporting standards. He has approved the release of this announcement.

For further information, please contact:

Further details are available from the Company's website, including its Glenover rare earth and phosphate project, its Nevada gold-copper properties in the USA, as well as a copy of this announcement:
www.galileoresources.com

 

You can also follow Galileo on Twitter: @GalileoResource

 

For further information, please contact:

 

Andrew Sarosi, Executive Director	Tel +44 (0) 1752 221937 /020 7584 2155
Beaumont Cornish Limited – Nomad Roland Cornish/James Biddle	Tel +44 (0) 20 7628 3396
Beaufort Securities Limited – Broker Jon Belliss	Tel +44 (0) 20 7382 8416

 

Technical Glossary

Au                          Gold

Ag                           Silver

As                           Arsenic

Breccia                 a rock composed of broken fragments of minerals or rock cemented together by a fine-grained matrix

Caldera                a large volcanic crater, especially one formed by a major eruption leading to the collapse of the mouth of the volcano.

Dike                       a later vertical rock between two layers of older rock

Epithermal         deposition from warm mineralised waters at shallow depth

Hg                           mercury

Jasperoid            rock formed from hydrothermal activity giving rise to Jasper, an opaque, impure variety of silica

Rhyolite               an igneous, volcanic rock, of silica-rich composition

Porphyry             textural term for an igneous rock consisting of large-grained crystals 

Stibnite                antimony sulphide mineral the chief ore of antimony

Tectonics             geologic process, which controls the structure and properties of the Earth's crust, 

Tertiary                a geological period of beginning about 65 million years ago

Tuff                        an igneous rock formed from the products of an explosive volcanic eruption

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCSEDFEFFMSEDL

Close

×

RNS Number : 5992V

Oxford Pharmascience Group PLC

19 April 2016

 

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience Announces Positive Regulatory Advice from MHRA on OXPzeroTM NSAIDs programme

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, announces that it has received clear and positive feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) on the UK regulatory pathway to obtain marketing authorisation for OXPzeroTM Ibuprofen. 

The Company currently has OXPzeroTM variants of two non-steroidal anti-inflammatory drug (NSAID) molecules in clinical development, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen.  These leverage the company's proprietary technology platform which aims to mask the bitter taste and irritation of NSAIDs and to provide reduced risk of gastrointestinal (GI) side effects.  Ibuprofen and naproxen are the two dominant NSAID molecules in the pain relief and anti-inflammatory sector, with combined worldwide sales in excess of $5bn per annum.(1)  The Company is in ongoing partnering discussions relating to its OXPzeroTM assets.

The recently received feedback follows a scientific advice meeting with the MHRA in early March on the development programme for OXPzeroTM Ibuprofen.  Specific key elements of the MHRA feedback received are:

·    OXPzeroTM Ibuprofen can be classified as a new salt form of Ibuprofen, not a new active substance or combination product, which greatly simplifies the regulatory pathway

·    The phase III study protocol for the product registration application with improved GI safety claim has been clarified

Marcelo Bravo, Chief Executive Officer of Oxford Pharmascience, commented:

"We are very pleased with the outcome of this meeting. The MHRA's feedback has provided clear direction for the pivotal studies required to gain approval of marketing authorisation for OXPzeroTM Ibuprofen.  This gives us a clear understanding of the timelines and associated investment required. We believe this puts us in a strong position as we continue with our partnering discussion process for both OXPzeroTM Ibuprofen and Naproxen."

 

Further information

The Company has obtained confirmation from the MHRA that OXPzeroTM Ibuprofen can be classified as a new salt form of ibuprofen and not a new active substance or combination product which greatly simplifies the regulatory pathway.  During this meeting only OXPzeroTM Ibuprofen was discussed, however, it is the Company's opinion that the MHRA feedback received is equally applicable to OXPzeroTM Naproxen and to OXPzeroTM NSAIDs in general.  Following this scientific advice meeting, the Company can confirm that the MHRA has provided guidance on its requirements for the pivotal development programme of OXPzeroTM Ibuprofen. The most appropriate legal basis of application for the over-the-counter and prescription strength product marketing authorisation applications was also confirmed – bioequivalent products will follow the 10(3) route, while non-bioequivalent products will follow the 8(3) route and require an additional single dose, dental pain study to prove the efficacy of OXPzeroTM Ibuprofen.

OXPzeroTM Ibuprofen and OXPzeroTM Naproxen compounds have been shown to deliver a range of key benefits that can be leveraged across multiple differentiated product applications.  Specifically, by comparison with generic NSAIDs, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen:

·    are milder in the GI tract, delivering major reduction in severe GI mucosal damage;

·    significantly mask the bitter taste/burn associated with NSAIDs; and

·    deliver an attractive PK profile with adaptable drug release properties.

 

NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day.(1)

 

For further information:

Oxford Pharmascience Group Plc   

Marcelo Bravo, Chief Executive          +44 20 7554 5875

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer                 +44 20 7496 3000

 

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take.  The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance.  By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCGUGDSIBBBGLC

Close

×

RNS Number : 4486V

Epistem Holdings plc

18 April 2016

 

RNS Press Release

For release: 18 April 2016

 

Epistem Begins Full Commercial Launch for Genedrive® Tuberculosis Tests in India

 

Genedrive® Enables Early Detection of TB and Antibiotic Resistance Without Need for Central Laboratory Facilities

 

 

Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces today that alongside its Indian commercialisation partner, Xcelris Labs, the Company has begun the full commercial launch for its Genedrive® tuberculosis (TB) and antibiotic resistance test.

 

Xcelris Labs, one of India's leading genomics products and services testing companies, initially intends to target Genedrive® at the country's approximately 5,000 private clinical laboratories to provide rapid point-of-care molecular identification and antibiotic resistance/drug susceptibility testing for TB. This accepted PCR based molecular diagnostic technique has generally only been available through selected large hospital central laboratory settings. Genedrive®'s low system cost, ease of use and robustness has the potential to greatly increase the wider adoption and availablility of sophisticated molecular diagnostic analysis and consequently patients' access to testing in India.

 

David Budd, CEO of Epistem, commented "Full commercial TB launch in India is an important next step in the commercialisation of Genedrive®. For the majority of patients who cannot access large reference hospitals and clinics, TB testing in India currently relies on conventional technologies such as microscopy and cell culture to detect infection and determine the most appropriate treatment. Genedrive® offers the ability to detect infection and antibiotic resistance in hours rather than days with important implications for more immediate and effective treatment, and the prevention of  spread of infection. The target pricing of Genedrive® and TB test cartridges makes our product an attractive commercial and clinical alternative to traditional diagnostic techniques."

 

Milina Bose, Executive Director and Vice President of Xcelris said "There are more than 30 million smear microscopy tests conducted in India a year with many carried out in smaller and medium sized private laboratories. Our commercial teams are very excited to now be commercialising Genedrive® and will initally be marketing the system and assays to laboratories outside of the traditional public facilities where molecular TB testing now occurs. We believe that providing these laboratories with the ability to carry out molecular testing with Genedrive® will be very attractive to them and impact positively on patient treatment options in India."

 

 

 

– Ends –

 

For further details please contact:

Epistem Holdings Plc

David Budd: CEO                                                                                                      +44 (0)161 606 7258

John Rylands: Finance Director

 

Peel Hunt LLP

James Steel                                                                                                              +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                           +44 (0)203 709 5700

Matthew Neal

epistem@consilium-comms.com 

 

Notes to Editors

 

About TB

Tuberculosis is the largest single infectious cause of death among young people and adults today and accounts for one quarter of all preventable adult deaths in developing countries. There were 9.6m new cases in 2014. TB can be treated with antibiotics with an 80% success rate but conventional diagnosis for TB is time consuming reliant on older tools. New molecular test approaches are the fastest growing segment in TB testing but existing technologies are not designed to reach out of large hospitals to smaller laboratories where most tests are currently run. Genedrive®'s low cost, speed-to-result, small size and robustness has the potential to extend access to sophisticated molecular testing outside a centralised laboratory setting.

 

About Epistem

Epistem is a personalised medicine and biotechnology company developing innovative molecular diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com

 

About Xcelris

Xcelris Genomics is part of the global Abellon business group with interests in diverse areas including clean energy, agrisciences, and genomics, as well as various initiatives in education and social development. Throughout India, Xcelris is a leading company in Genomics products and services and is  providing diagnostic testing services in the specialised field of Medical Genetics and Nutrigenomics.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

PRLIRMBTMBABTTF

Close

×

RNS Number : 2831V

Vela Technologies PLC

15 April 2016

 

15 April 2016

Vela Technologies plc

("Vela" or the "Company")

 

Completion of investment in Portr Limited

 

Further to the announcement of 8 March 2016 the Board of Vela (AIM: VELA), the investing company focused on early stage and pre-IPO disruptive technology investments, is pleased to announce that Vela has completed its investment of £151,343 in Portr Limited ("Portr"), the owner of the on-demand airport luggage transfer service, AirPortr. The funds were paid by Vela to Portr in early April 2016.  

Vela has been informed by Portr that they have now successfully completed their fundraising exercise with existing shareholders to raise £3 million (the "Portr Fundraising").

Following completion of the investment Vela has an interest in 101,989 shares in Portr which represents 3.9% of Portr's issued share capital following completion of the Portr Fundraising. Vela's enlarged shareholding in Portr is valued at £1.079 million, based on the price of the Portr Fundraising. Following the investment of £151,343 in the Portr Fundraising, Vela has invested a total of £251,343 in cash in Portr over three funding rounds.

Further details on Portr and the background to the investment are contained in the announcement of 8 March 2016.

For further information please contact:

Vela Technologies plc
Brent Fitzpatrick, Non-Executive Chairman Antony Laiker, Director		Tel: +44 (0) 7802 262 443
Allenby Capital Limited (Nominated Adviser)
Nick Athanas/Katrina Perez/James Reeve		Tel: +44 (0) 20 3328 5656
Smaller Company Capital Limited (Broker) Rupert Williams/Jeremy Woodgate	Tel: +44 (0) 20 3651 2910

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCGGUQWCUPQGMC

Close

×

Neville Registrars is delighted to welcome Osirium Technologies plc as the newest addtion to its list of client companies.

The Osirium team have intelligently combined the latest generation of Cyber-Security and Automation technology to create the world’s first, built-for-purpose, Privileged Protection and Task Automation solution for the Hybrid-Cloud world.

Further information can be found on the Company's website: https://osirium.com/

Close

×

RNS Number : 2600V

Flowgroup plc

14 April 2016

 

 

Flowgroup plc

("Flowgroup" or the "Company")

 

First commercial installations of Flow boiler now complete

 

Flowgroup plc (AIM: FLOW), which provides innovative energy technologies, energy supply and energy services, announces that the first commercial installs of the Flow boiler in customer homes have been completed. 

 

These new customer installs were completed on time and to plan. The installed Flow boilers are performing in line with expectations, both heating the home and generating electricity.

 

As previously announced, the Company will now continue with installations, ramping up over the next six months and aiming for higher volume sales in the winter months.

 

A blog post with photos of an install is available at: http://www.flowenergy.uk.com/blog/flow-boiler/flow-boiler-first-installs/

 

Tony Stiff, Chief Executive Officer of Flowgroup, commented: "We are very pleased to announce that we have completed the first commercial customer installations of the Flow boiler which are providing both heat and power. Initial customer satisfaction is high and the Flow Brand Ambassadors involved in the first installs are excited to be involved in making history by installing a real world's first – an affordable, electricity-generating boiler. We will continue with installations through the summer before ramping up to higher volume in the key winter period. I'd like to thank every member of our team for the effort they have put in to bring us to this historic moment."   

 

Flowgroup plc		www.flowgroup.uk.com
Tony Stiff, Chief Executive Officer, Flowgroup plc		Tel: +44 (0)20 3137 4525
Walbrook PR Ltd	Tel: +44 (0)20 7933 8780 or flowgroup@walbrookpr.com
Paul McManus (Media Relations)			Mob: 07980 541 893

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAEALLLFFKKEFF

Close

×

RNS Number : 7173U

Midatech Pharma PLC

11 April 2016

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech's Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US

 

–  Midatech further expands its commercial footprint in US, supporting the Zuplenz® launch

 

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces its forthcoming full commercial launch of Zuplenz® (ondansetron) Oral Soluble Film to prevent post-operative, chemotherapy and radiation-induced nausea and vomiting, in the United States.

 

In support of the Zuplenz product launch and Midatech's growing oncology supportive care portfolio, Midatech has invested in a significant expansion of its commercial organization, including additional field sales representation, field sales management, national accounts personnel, and marketing and internal support staff. Midatech's newly expanded commercial team will attend the Zuplenz launch meeting Tuesday to Friday of this week in Dallas, Texas.

 

Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "Zuplenz is a valuable treatment option that offers convenient relief from one of the most debilitating side-effects of common cancer treatments. The product launch of Zuplenz represents yet another step forward for Midatech and further leverages our commercial infrastructure in the US. Zuplenz is a perfect example of our rapidly growing portfolio of marketed oncology products and will further contribute to our growing revenue stream."

 

Zuplenz, acquired into Midatech's portfolio of marketed oncology products in December 2015, is a 5HT3 receptor antagonist. The novel oral soluble film technology used by Zuplenz offers an innovative approach to ondansetron delivery that, in comparison to other delivery methods, provides several key cancer patient benefits including a non-gritty delivery mechanism, non-patch delivery, discreet on-the-go usage, removal of the burden of swallowing pills during emesis, and no sedative side effects.

 

Jerilyn Arnold, Senior RN, Oncology Nurse Specialist at Texas Oncology, said: "In practice, patients often find non-tablet therapies for CINV and RINV sub-optimal due to gritty residue, potential need for the patient to wear a patch and possible exacerbation of their nausea and vomiting due to various other product characteristics. Together, these limitations contribute to reduced compliance and efficacy often leading to various morbidities associated with CINV and RINV. Zuplenz provides an excellent localised therapy solution for the treatment of both CINV and RINV because the novel formulation avoids the pitfalls that come with other ondansetron products."

 

According to data from Symphony Health Solutions, there were approximately twenty million prescriptions written in 2015 in the US for ondansetron, with more than half of the ondansetron market being fulfilled with oral dissolving tablets. Zuplenz's unique profile and benefits, combined with both excellent commercial reimbursement and Midatech Pharma's zero-dollar out-of-pocket patient co-pay program (for qualifying individuals) provides a strong and proven platform to launch Zuplenz® into the US market.

 

David Benharris, MTPUS President, said: "We are very excited to add a unique and proven CINV/RINV product to our oncology supportive care portfolio. The planned growth of our commercial organisation in support of the Zuplenz launch allows us to add significant share of voice amongst the leading writers of oncology supportive care products, while further strengthening and expanding upon our relationships in these important offices."

 

Note to investors

Midatech will issue its 2015 Full Year Results on Wednesday 13 April 2016. Dr Jim Phillips, Chief Executive Officer, and Nick Robbins-Cherry, Chief Financial Officer, will host a call and a live Q&A session for analysts and investors at 1300 BST / 0800 EDT.

 

– ENDS –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Atholl Tweedie / Duncan Monteith

Corporate Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

RBC Europe Limited (Joint Broker)

Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman

Tel: +44 (0)207 653 4000

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

About Zuplenz® (ondansetron) Oral Soluble Film

Zuplenz® (ondansetron) Oral Soluble Film was acquired by Midatech Pharma (AIM: MTPH; Nasdaq: MTP) from Galena Biopharma, Inc. (Nasdaq: GALE) in December 2015. The product is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. Zuplenz uses MonoSol's proprietary PharmFilm® technology, an oral soluble film that dissolves on the tongue in less than 30 seconds, thereby eliminating the burden of swallowing pills during periods of emesis. The active pharmaceutical ingredient in Zuplenz®, ondansetron, belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.  Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.  Discontinue using Zuplenz at the first sign of hypersensitivity. For more information and full prescribing information on Zuplenz, please visit www.zuplenz.com.

 

Forward-Looking Statement

 

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the anticipated medical benefits of Zuplenz, our expected revenues, market and growth opportunities and other benefits associated Zuplenz® and other statements that are not historical fact. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

PRLGGUWUCUPQPGU

Close